miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2
Multiple endocrine neoplasia type 1 (MEN1), caused by mutations in the MEN1 gene encoding menin, is an autosomal dominant disorder characterised by the combined occurrence of parathyroid, pituitary and pancreatic neuroendocrine tumours (NETs). Development of these tumours is associated with wide var...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Society for Endocrinology
2022
|
| _version_ | 1797107536310042624 |
|---|---|
| author | Kooblall, KG Stokes, VJ Shariq, OA English, KA Stevenson, M Broxholme, J Wright, B Lockstone, HE Buck, D Grozinsky-Glasberg, S Yates, CJ Thakker, RV Lines, K |
| author_facet | Kooblall, KG Stokes, VJ Shariq, OA English, KA Stevenson, M Broxholme, J Wright, B Lockstone, HE Buck, D Grozinsky-Glasberg, S Yates, CJ Thakker, RV Lines, K |
| author_sort | Kooblall, KG |
| collection | OXFORD |
| description | Multiple endocrine neoplasia type 1 (MEN1), caused by mutations in the MEN1 gene encoding menin, is an autosomal dominant disorder characterised by the combined occurrence of parathyroid, pituitary and pancreatic neuroendocrine tumours (NETs). Development of these tumours is associated with wide variations in their severity, order and ages (from <5 to >80 years), requiring life-long screening. To improve tumour surveillance and quality of life, better circulating biomarkers, particularly for pancreatic NETs that are associated with higher mortality, are required. We, therefore, examined the expression of circulating miRNA in the serum of MEN1 patients. Initial profiling analysis followed by qRT-PCR validation studies identified miR-3156-5p to be significantly downregulated (−1.3 to 5.8-fold, P < 0.05–0.0005) in nine MEN1 patients, compared to matched unaffected relatives. MEN1 knock-down experiments in BON-1 human pancreatic NET cells resulted in reduced MEN1 (49%, P < 0.05), menin (54%, P < 0.05) and miR-3156-5p expression (20%, P < 0.005), compared to control-treated cells, suggesting that miR-3156-5p downregulation is a consequence of loss of MEN1 expression. In silico analysis identified mortality factor 4-like 2 (MOR4FL2) as a potential target of miR-3156-5p, and in vitro functional studies in BON-1 cells transfected with either miR-3156-5p mimic or inhibitors showed that the miR-3156-5p mimic significantly reduced MORF4L2 protein expression (46%, P < 0.005), while miR-3156-5p inhibitor significantly increased MORF4L2 expression (1.5-fold, P < 0.05), compared to control-treated cells, thereby confirming that miR-3156-5p regulates MORF4L2 expression. Thus, the inverse relationship between miR-3156-5p and MORF4L2 expression represents a potential serum biomarker that could facilitate the detection of NET occurrence in MEN1 patients. |
| first_indexed | 2024-03-07T07:17:32Z |
| format | Journal article |
| id | oxford-uuid:e7b01d69-e314-4daa-9ac9-5b7323023ed4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:17:32Z |
| publishDate | 2022 |
| publisher | Society for Endocrinology |
| record_format | dspace |
| spelling | oxford-uuid:e7b01d69-e314-4daa-9ac9-5b7323023ed42022-08-18T18:02:04ZmiR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e7b01d69-e314-4daa-9ac9-5b7323023ed4EnglishSymplectic ElementsSociety for Endocrinology2022Kooblall, KGStokes, VJShariq, OAEnglish, KAStevenson, MBroxholme, JWright, BLockstone, HEBuck, DGrozinsky-Glasberg, SYates, CJThakker, RVLines, KMultiple endocrine neoplasia type 1 (MEN1), caused by mutations in the MEN1 gene encoding menin, is an autosomal dominant disorder characterised by the combined occurrence of parathyroid, pituitary and pancreatic neuroendocrine tumours (NETs). Development of these tumours is associated with wide variations in their severity, order and ages (from <5 to >80 years), requiring life-long screening. To improve tumour surveillance and quality of life, better circulating biomarkers, particularly for pancreatic NETs that are associated with higher mortality, are required. We, therefore, examined the expression of circulating miRNA in the serum of MEN1 patients. Initial profiling analysis followed by qRT-PCR validation studies identified miR-3156-5p to be significantly downregulated (−1.3 to 5.8-fold, P < 0.05–0.0005) in nine MEN1 patients, compared to matched unaffected relatives. MEN1 knock-down experiments in BON-1 human pancreatic NET cells resulted in reduced MEN1 (49%, P < 0.05), menin (54%, P < 0.05) and miR-3156-5p expression (20%, P < 0.005), compared to control-treated cells, suggesting that miR-3156-5p downregulation is a consequence of loss of MEN1 expression. In silico analysis identified mortality factor 4-like 2 (MOR4FL2) as a potential target of miR-3156-5p, and in vitro functional studies in BON-1 cells transfected with either miR-3156-5p mimic or inhibitors showed that the miR-3156-5p mimic significantly reduced MORF4L2 protein expression (46%, P < 0.005), while miR-3156-5p inhibitor significantly increased MORF4L2 expression (1.5-fold, P < 0.05), compared to control-treated cells, thereby confirming that miR-3156-5p regulates MORF4L2 expression. Thus, the inverse relationship between miR-3156-5p and MORF4L2 expression represents a potential serum biomarker that could facilitate the detection of NET occurrence in MEN1 patients. |
| spellingShingle | Kooblall, KG Stokes, VJ Shariq, OA English, KA Stevenson, M Broxholme, J Wright, B Lockstone, HE Buck, D Grozinsky-Glasberg, S Yates, CJ Thakker, RV Lines, K miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2 |
| title | miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2 |
| title_full | miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2 |
| title_fullStr | miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2 |
| title_full_unstemmed | miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2 |
| title_short | miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2 |
| title_sort | mir 3156 5p is downregulated in serum of men1 patients and regulates expression of morf4l2 |
| work_keys_str_mv | AT kooblallkg mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT stokesvj mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT shariqoa mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT englishka mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT stevensonm mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT broxholmej mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT wrightb mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT lockstonehe mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT buckd mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT grozinskyglasbergs mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT yatescj mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT thakkerrv mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 AT linesk mir31565pisdownregulatedinserumofmen1patientsandregulatesexpressionofmorf4l2 |